

Sanofi
Form 6-K
January 18, 2012

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of January 2012

Commission File Number: 001-31368

SANOFI

(Translation of registrant's name into English)

174, avenue de France, 75013 Paris, FRANCE

(Address of principal executive offices)

Edgar Filing: Sanofi - Form 6-K

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If Yes marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

In January 2012, Sanofi issued the press releases attached hereto as Exhibits 99.1 and 99.2 which are incorporated herein by reference.

Exhibit List

Exhibit	No.	Description
Exhibit 99.1		Press release dated January 18, 2012: Genzyme Announces European Approval of Framingham Manufacturing Plant.
Exhibit 99.2		Press release dated January 10, 2012: <i>Sanofi</i> and Venture Capital Firms, <i>Third Rock Ventures and Greylock Partners</i> , Jointly Launch <i>Warp Drive Bio</i> , a Biotechnology Company Combining Innovative Genomics Technologies for Natural Products Drug Discovery.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: January 18, 2012

SANOFI

By /S/ John Felitti
Name: John Felitti
Title: Associate Vice President,
Corporate Law, Financial & Securities Law

Exhibit Index

Exhibit	No.	Description
Exhibit 99.1		Press release dated January 18, 2012: Genzyme Announces European Approval of Framingham Manufacturing Plant.
Exhibit 99.2		Press release dated January 10, 2012: <i>Sanofi</i> and Venture Capital Firms, <i>Third Rock Ventures</i> and <i>Greylock</i> Partners, Jointly Launch <i>Warp Drive Bio</i> , a Biotechnology Company Combining Innovative Genomics Technologies for Natural Products Drug Discovery.